The regulatory effects of the apelin/APJ system on depression: A prospective therapeutic target.
APJ
Antidepressant effects
Apelin
Central nervous system
Depression
Journal
Neuropeptides
ISSN: 1532-2785
Titre abrégé: Neuropeptides
Pays: Netherlands
ID NLM: 8103156
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
08
06
2023
revised:
08
09
2023
accepted:
08
09
2023
medline:
20
11
2023
pubmed:
17
9
2023
entrez:
16
9
2023
Statut:
ppublish
Résumé
Depression is a debilitating neuropsychological disorder characterized by high incidence, high recurrence, high suicide, and high disability rates, which poses serious threats to human health and imposes heavy psychological and economic burdens on family and society. The pathogenesis of depression is extremely complex, and its etiology is multifactorial. Mounting evidence suggests that apelin and apelin receptor APJ, which compose the apelin/APJ system, are related to the development of depression. However, the specific mechanism is still unclear, and research in this area in human is still insufficient. Acceleration of research into the regulatory effects and underlying mechanisms of the apelin/APJ system in depression may identify attractive therapeutic targets and contribute to the development of novel intervention strategies against this devastating psychological disorder. In this review, we mainly discuss the regulatory effects of apelin/APJ system on depression and its potential therapeutic applications.
Identifiants
pubmed: 37716179
pii: S0143-4179(23)00063-X
doi: 10.1016/j.npep.2023.102382
pii:
doi:
Substances chimiques
Apelin
0
Apelin Receptors
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102382Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare no conflict of interest.